IJCM  Vol.9 No.8 , August 2018
Curative Effect Analysis of Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis with Different Bone Turnover Rates
Abstract: Objective: To explore the clinical efficacy of Zoledronic Acid Injection in the treatment of postmenopausal osteoporosis with different bone turnover rates. Methods: A total of 63 patients diagnosed with postmenopausal osteoporosis were included in this study. Each patient was administrated 5 mg/100mL Zoledronic Acid (Aclasta) intravenously once and then given a one-year prescription of 600 mg/d oral Caltrate. The bone turnover parameters (PINP, β-cross, N-MID) were measured prior to the injection of Zoledronic Acid while the bone mineral density (BMD) and the pain scores of each patient were tested before treatment and after the one-year medication. On this basis, the patients were divided into several groups according to their bone turnover rates for intergroup comparison of treatment outcomes. Results: BMD results and pain scores of all participants were significantly improved at different levels after treatment. However, these improvements had no significant differences between the patients with high and low bone turnover rates. Conclusion: Zoledronic Acid Injection can relieve bone pain, enhance the quality of life and increase the BMD in patients with postmenopausal osteoporosis, regardless of the bone turnover status.
Cite this paper: Jie, S. , Deng, J. , Lin, C. , Cai, X. and Cai, D. (2018) Curative Effect Analysis of Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis with Different Bone Turnover Rates. International Journal of Clinical Medicine, 9, 621-628. doi: 10.4236/ijcm.2018.98052.

[1]   Huang, S., Lin, H., Zhu, X., et al. (2014) Zoledronic Acid Increases Bone Mineral Density and Improves Health-Related Quality of Life over Two Years of Treatment in Chinese Women with Postmenopausal Osteoporosis. Endokrynologia Polska, 65, 96-104.

[2]   Gauthier, K., Bai, A., Perras, C., et al. (2012) Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis: Clinical Effectiveness and Harms. Canadian Agency for Drugs and Technologies in Health, Ottawa, ON.

[3]   Nishizawa, Y., Ohta, H., Miura, M., et al. (2013) Guidelines for the Use of Bone Metabolic Markers in the Diagnosis and Treatment of Osteoporosis. Journal of Bone and Mineral Metabolism, 31, 1-15.

[4]   Cavalier, E., Bergmann, P., Bruyere, O., et al. (2016) The Role of Biochemical of Bone Turnover Markers in Osteoporosis and Metabolic Bone Disease: A Consensus Paper of the Belgian Bone Club. Osteoporosis International, 27, 2181-2195.

[5]   Deal, C. (2009) Potential New Drug Targets for Osteoporosis. Nature Clinical Practice Rheumatology, 5, 20-27.

[6]   Ruza, I., Mirfakhraee, S., Orwoll, E., et al. (2013) Clinical Experience with Intravenous Zoledronic Acid in the Treatment of Male Osteoporosis: Evidence and Opinions. Therapeutic Advances in Musculoskeletal Disease, 5, 182-198.

[7]   Tasci, I., Safer, U., Cintosun, U., et al. (2016) Zoledronic Acid Use and Risk of Cognitive Decline among Elderly Women and Men with Osteoporosis. Endocrine, Metabolic & Immune Disorders Drug Targets, 16, 32-38.

[8]   Gamsjaeger, S., Buchinger, B., Zwettler, E., et al. (2011) Bone Material Properties in Actively Bone-Forming Trabeculae in Postmenopausal Women with Osteoporosis after Three Years of Treatment with Once-Yearly Zoledronic Acid. Journal of Bone and Mineral Research, 26, 12-18.

[9]   Sheedy, K.C., Camara, M.I. and Camacho, P.M. (2015) Comparison of the Efficacy, Adverse Effects, and Cost of Zoledronic Acid and Denosumab in the Treatment of Osteoporosis. Endocrine Practice, 21, 275-279.

[10]   Carmona, R. and Adachi, R. (2009) Treatment of Postmenopausal Osteoporosis, Patient Perspectives—Focus on Once Yearly Zoledronic Acid. Patient Preference and Adherence, 3, 189-193.

[11]   Wang, C. (2017) Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. American Journal of Therapeutics, 24, e544-e552.

[12]   Cremers, S. and Garnero, P. (2006) Biochemical Markers of Bone Turnover in the Clinical Development of Drugs for Osteoporosis and Metastatic Bone Disease: Potential Uses and Pitfalls. Drugs, 66, 2031-2058.

[13]   Miura, M. (2013) Evaluation of Bone for Using of Bone Metabolic Markers in the Diagnosis and Treatment of Osteoporosis. Clinical Calcium, 23, 325-338.

[14]   Chao, M., Hua, Q., Yingfeng, Z., et al. (2013) Study on the Role of Zoledronic Acid in Treatment of Postmenopausal Osteoporosis Women. Pakistan Journal of Medical Sciences, 29, 1381-1384.